News

2015

• September - i3 Pharmaceuticals was formed with strong capital backing from private investors. 
• October – Leased laboratory space in Plymouth Meeting, PA.

2016

• January - Acquired a 150,000 square feet building in Warminster, PA.
• December - Moved into the newly constructed facility with state of the art research and analytical laboratories, pilot & commercial manufacturing plants and warehouse.

2018

• June – Filed first ANDA with the US FDA for a product for which there was formerly no generic alternative available.
• December - Successful FDA Prior Approval and GMP inspection.

2020

• April - Gained FDA ANDA approval for Ramelteon 8mg tablets.
• September - Gained FDA ANDA approval for Chlorzoxazone 375 and 750mg tablets.

2021

• June - Successful FDA full, virtual GMP inspection.
• September - Gained FDA ANDA approval for Selegiline HCl 5mg tablets.

2022

• February - Launched Selegiline HCl 5mg tablets into US Market. First product commercialized in the i3 label.
• October - Launched Ranolazine 500mg and 1000mg extended-release tablets into US Market.

2023

• March - Successful FDA cGMP Inspection and five-product Prior Approval Inspection.
• October - Launched Posaconazole DR 100mg tablets into US Market.
• November - Launched Maraviroc 150mg and 300mg tablets into US Market.
• December - Launched Guanfacine 1mg and 2mg tablets into US Market.